In particular, CLL patients displayed a significant up-regulation of DPF3 mRNA levels in PB compared to controls, while AML and CML patients displayed lower DPF3 mRNA levels compared to its expression in the PB and BM of controls (Table 1, Figure 3). The gene discussed is DPF3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.